Oticon Medical announced FDA clearance for its first active transcutaneous bone conduction hearing system, the Sentio System.
The system includes Sentio 1 Mini, an external sound processor, and Sentio Ti Implant, placed under the skin. It is the smallest transcutaneous system available to date.
While Ponto and other percutaneous bone-anchored hearing systems use skin-protruding abutments, the Sentio System provides an alternative, keeping the skin intact.
The Sentio 1 Mini is designed with a focus on user comfort and ease of use. The device's design and slim profile make it 26% lighter than an alternative. It gives access to a 360-degree sound experience and offers the widest bandwidth of 9.5kHz.
Sentio Ti is an implant developed to support patient’s progressive hearing loss, without the need for additional surgeries. It is designed and verified for a higher maximum force output, so that patients can rely on its ability to handle more powerful sound processors.
Sentio System is indicated for candidates aged 12 and older who have been diagnosed with conductive hearing loss, mixed hearing loss, or single-sided deafness.
